- KONTAKT
- AFS
- Business
- Bussiness
- Car
- Career
- Celebrity
- Digital Products
- Education
- Entertainment
- Fashion
- Film
- Food
- Games
- General Health
- Health
- Health Awareness
- Healthy
- Healthy Lifestyle
- History Facts
- Household Appliances
- Internet
- Investment
- Law
- Lifestyle
- Loans&Mortgages
- Luxury Life Style
- movie
- Music
- Nature
- News
- Opinion
- panorama
- Pet
- Plant
- Politics
- promis
- Recommends
- Science
- Self-care
- services
- Smart Phone
- sport
- Sports
- Style
- Technology
- tire
- Travel
- US
- World

When you buy through links on our articles, Future and its syndication partners may earn a commission.
Update for 7:40 p.m. ET on Dec. 19: Innospace has called off today's planned launch of the Spaceward mission due to a technical issue. A new target date has not yet been announced.
South Korean startup Innospace is set to attempt its first orbital launch today (Dec. 19), and you can watch the action live.
Liftoff is currently scheduled for 7:30 p.m. EST (9:30 p.m. local time and 0030 GMT on Dec. 20) from the Alcantara Space Center in Brazil. Innospace's Hanbit-Nano rocket will aim to insert five small satellites for customers from Brazil and India into a 186-mile-high (300 kilometers) orbit and mark a first for a private Korean company.
Watch it live here at Space.com, courtesy of Innospace, or directly via the company. Coverage will begin at 6:30 p.m. EST (2330 GMT).
"Hanbit-Nano has been successfully rolled out from the integration facility and transported to the launch pad ahead of liftoff. Preparations for the Spaceward mission are right on track," Innospace said Wednesday (Dec. 16) in a post on the social media platform X.
The 57-foot-tall (17.3 meters) rocket is designed to be able to launch 198 pounds (90 kilograms) into a sun-synchronous orbit from Brazil. The rocket's first-stage hybrid engine burns paraffin and liquid oxygen while the upper stage uses methane and liquid oxygen or paraffin and liquid oxygen, depending on its configuration.
Innospace CEO Kim Soo-jong told Space.com at the International Astronautical Congress in Sydney, Australia, in October that the company was established in 2017 and employs 260 people.
"All of our technology is developed by ourselves. The engineers are Korean, and the development is fully indigenous," Kim said. "Korea has built an ecosystem to develop a launch vehicle. We work with more than 100 supply-chain companies in South Korea," he added.
Kim said Innospace is very focused on the global market. "We already have around 14 contracts with global satellite companies."
A lot is riding on this first launch. Kim said that Hanbit-Micro, an advanced model of Hanbit-Nano that can carry 375 pounds (170 kg) to orbit, is set to begin commercial flights early next year, should all go according to plan.
Today's launch was originally scheduled for Wednesday (Dec. 17), but Innospace pushed it back two days to replace a part in the cooling system of the rocket's first stage.
NEUESTE BEITRÄGE
- 1
Bomb blast in packed Nigerian mosque kills five - 2
Turkey's Erdogan denounces Israel-Greece-Cyprus trilateral summit, affirms support for Gaza - 3
Eleven arrested over mass shooting in South Africa tavern - 4
‘Integral part of our nation’: Herzog visits Franciscan Sisters in Jerusalem ahead of Christmas - 5
Chicago reports first rabies-positive dog in 61 years. What we know.
Ähnliche Artikel
Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients
Lilly, Novo lock horns in India's obesity drug race
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
Indian rocket launches record-breaking BlueBird 6 smartphone satellite to orbit (video)
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
Weight-loss pill approval set to accelerate food industry product overhauls
I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
Rick Steves' Favorite Time To Visit Spain Has Lower Prices And Fewer Crowds
US FDA grants market authorization to six on! PLUS nicotine pouch products
BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet














